FINWIRES · TerminalLIVE
FINWIRES

IGO's Shareholder Upside Muted Despite Robust Lithium Market, Says Jefferies

By

-- IGO's (ASX:IGO) structural issues and weak performance at its key Greenbushes asset are limiting shareholder exposure to upside despite a strong lithium market, Jefferies said in a note on Monday.

The company reduced the fiscal 2026 spodumene production guidance from the Greenbushes lithium mine in Western Australia to 1.38 million tonnes to 1.43 million tonnes, reflecting performance year-to-date and CGP3 ramp-up expectations for the June quarter. Jefferies had expected Greenbushes 2026 production of 1.5 million tonnes.

It also lowered capital expenditure outlook for the operation to AU$400 million to AU$450 million from AU$575 million to AU$675 million, compared with Jefferies' projection of AU$565 million.

The company's Kwinana asset remains economically challenged and a large shutdown in April and May is to impact its June quarter output, the investment firm added.

Jefferies reaffirmed a hold rating on IGO and cut its price target to AU$7 from AU$8.

Related Articles

Asia

Telix Says Marketing Authorization Application for Glioma Imaging Candidate Accepted for Review in Europe; Shares Up 3%

Telix Pharmaceuticals (ASX:TLX) said Friday its marketing authorization application filed in Europe for TLX101-Px, its glioma imaging candidate, has been validated and accepted for review, moving into a 210-day active assessment phase.In a statement, the company said it is seeking a broad clinical label, reflective of current clinical practice guidelines, with national marketing authorizations expected to follow shortly after a positive outcome at day 210.The company said it aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications.TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx, which has been granted orphan drug designation in Europe and the US, per the statement.The phase 3 IPAX-BrIGHT trial of TLX101-Tx in patients with recurrent glioblastoma has started patient dosing internationally and is launching in multiple European countries, the company said.Telix Pharmaceuticals' shares were up 3% in recent Friday trade.

$ASX:TLX
Asia

Zozo's Profit Climbs 6% in Fiscal Year 2025

Zozo's (TYO:3092) profit attributable to owners of the parent rose 5.7% to 47.93 billion yen for the fiscal year 2025 from 45.35 billion yen a year earlier.The shopping mall operator's basic earnings per share increased to 54.11 yen from 50.90 yen a year ago, according to a Tokyo bourse filing on Thursday.Net sales climbed 7.2% to 228.37 billion yen for the full year ended March 31 from 213.13 billion yen in the prior year.The company declared a year-end dividend of 20 yen per share, payable from June 11.For the fiscal year 2026, the company expects attributable profit of 49.7 billion yen, EPS of 56.20 yen, and net sales of 241.9 billion yen.Zozo plans to pay interim and year-end dividends of 20 yen per share each for the year, which is higher than the amount in the year-ago period.

$TYO:3092
Asia

EML Payments Says Regulators Extend Date for Implementation of Required Guarantee Structure

EML Payments (ASX:EML) said the Australian Prudential Regulation Authority (APRA) and Reserve Bank of Australia (RBA) agreed to extend the date for implementation of the required authorized deposit-taking institution guarantee structure, subject to EML Payment Solutions showing "satisfactory progress" towards obtaining the guarantee via periodic reporting, according to a Friday Australian bourse filing.EML Payment Solutions is engaging with several domestic and international financial institutions, as well as legal advisors and trustee service providers, to design the required guarantee structure.The regulators had earlier said that they require the firm to obtain a guarantee from an authorized deposit-taking institution in respect of stored value liabilities for certain EML Payment Solutions programs by Thursday.

$ASX:EML